ORGO vs. KMDA, CRMD, VRCA, VTYX, NLTX, VNDA, URGN, AVIR, PROC, and NKTX
Should you be buying Organogenesis stock or one of its competitors? The main competitors of Organogenesis include Kamada (KMDA), CorMedix (CRMD), Verrica Pharmaceuticals (VRCA), Ventyx Biosciences (VTYX), Neoleukin Therapeutics (NLTX), Vanda Pharmaceuticals (VNDA), UroGen Pharma (URGN), Atea Pharmaceuticals (AVIR), Procaps Group (PROC), and Nkarta (NKTX). These companies are all part of the "pharmaceutical preparations" industry.
Kamada (NASDAQ:KMDA) and Organogenesis (NASDAQ:ORGO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, community ranking, profitability, earnings and institutional ownership.
Kamada has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Comparatively, Organogenesis has a beta of 1.6, indicating that its share price is 60% more volatile than the S&P 500.
Kamada currently has a consensus price target of $11.00, indicating a potential upside of 98.74%. Organogenesis has a consensus price target of $4.83, indicating a potential upside of 59.52%. Given Organogenesis' stronger consensus rating and higher possible upside, research analysts clearly believe Kamada is more favorable than Organogenesis.
Kamada has a net margin of 8.33% compared to Kamada's net margin of 1.34%. Organogenesis' return on equity of 5.50% beat Kamada's return on equity.
In the previous week, Kamada had 7 more articles in the media than Organogenesis. MarketBeat recorded 14 mentions for Kamada and 7 mentions for Organogenesis. Kamada's average media sentiment score of 1.05 beat Organogenesis' score of -0.01 indicating that Organogenesis is being referred to more favorably in the news media.
20.4% of Kamada shares are owned by institutional investors. Comparatively, 49.6% of Organogenesis shares are owned by institutional investors. 36.1% of Kamada shares are owned by insiders. Comparatively, 34.0% of Organogenesis shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Kamada received 213 more outperform votes than Organogenesis when rated by MarketBeat users. However, 66.21% of users gave Organogenesis an outperform vote while only 65.05% of users gave Kamada an outperform vote.
Kamada has higher earnings, but lower revenue than Organogenesis. Kamada is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.
Summary
Kamada beats Organogenesis on 11 of the 18 factors compared between the two stocks.
Get Organogenesis News Delivered to You Automatically
Sign up to receive the latest news and ratings for ORGO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ORGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Organogenesis Competitors List
Related Companies and Tools
